PCI Pharma Services (PCI) has launched its new contained packaging facility for the primary and secondary packaging of highly potent products at its new site near Dublin, Ireland. 
 
PCI manufactures highly potent molecules at its contained manufacturing facility located at its Tredegar site in Wales, UK. This latest investment in contained packaging capabilities at the PCI Ireland site allows for the highest standards of safety and regulatory adherence for specialized medicines. It is also part of PCI’s strategic initiative to develop its High Containment Operations (HCO) services globally. 
 
“We are very excited to officially launch our state-of-the-art high contained packaging facility here in Ireland,” said Bill Mitchell, president and chief executive officer.  “The recent acquisition of Millmount Healthcare and further investment in this newest specialized facility adds considerable capacity and capability to our global supply network, enabling us to meet our customers’ changing and evolving needs in many different geographies. Moreover, as our fourth acquisition outside the U.S. in the past four years, this expansion further demonstrates our ability to provide our clients with a comprehensive solution to any uncertainty brought upon by ongoing negotiations between the UK and EU as a result of the evolving Brexit situation.”
 
Since the acquisition of Millmount Healthcare, PCI has added approximately 30 positions at the Dublin area facilities and anticipates adding more than 100 positions over the next five years as the sites continue to expand and grow its operations.